Alaunos Therapeutics
TCRT
29 hedge funds and large institutions have $103K invested in Alaunos Therapeutics in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 4 closing their positions.
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0.09% less ownership
Funds ownership: 4.51% → 4.42% (-0.09%)
3% less funds holding
Funds holding: 30 → 29 (-1)
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
58% less capital inflows, than outflows
Capital inflows: $1.81K | Capital outflows: $4.28K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Tower Research Capital (TRC)
New York
|
+$863 |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$646 |
| 3 |
Barclays
London,
United Kingdom
|
+$280 |
| 4 |
Investment Management Corporation
Roanoke,
Virginia
|
+$10 |
| 5 |
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$7 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$3.03K |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$552 |
| 3 |
Morgan Stanley
New York
|
-$244 |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$229 |
| 5 |
Wells Fargo
San Francisco,
California
|
-$100 |
TCRT Hedge Fund Activity: Q1 2025 in Review
29 of the 7,487 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q1 2025, worth a combined $103K — down 25% from $137K a quarter earlier.
Fund positioning in TCRT was balanced in Q1 2025: 4 funds opened new positions, 4 closed out, 3 added to existing stakes and 6 trimmed.
The largest buyer was Tower Research Capital (TRC), adding an estimated $863. The largest seller was Citigroup, exiting entirely with an estimated $3.03K sold.
- 29 institutional investors held Alaunos Therapeutics (TCRT) as of Q1 2025, down from 30 in Q4 2024.
- Funds reported $103K of Alaunos Therapeutics stock for Q1 2025, down 25% quarter-over-quarter.
- 4 funds opened new Alaunos Therapeutics positions in Q1 2025 and 4 closed out, a net change of 0 holders.
- The largest Alaunos Therapeutics buyer in Q1 2025 was Tower Research Capital (TRC), an estimated $863 added.
- The largest Alaunos Therapeutics seller in Q1 2025 was Citigroup, an estimated $3.03K sold.
Based on aggregated 13F filings for Q1 2025.